Bowel Interest Group
  • HOME
  • ABOUT
    • MEET THE BOARD
    • CONTACT
  • WEBINARS
  • NEWS
  • RESOURCES
  • SUBSCRIBE
Select Page
Lilly reports positive data from its ulcerative colitis phase 3 trial

Lilly reports positive data from its ulcerative colitis phase 3 trial

Apr 12, 2021

Eli Lilly and Company  have announced that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe...
Could your patient’s chronic watery diarrhoea be Microscopic Colitis?

Could your patient’s chronic watery diarrhoea be Microscopic Colitis?

Oct 15, 2020

This resource outlines the key characteristics of Microscopic Colitis (MC) which is an inflammatory Bowel Disease that affects the large bowel (colon and rectum). The symptoms of Microscopic Colitis have some overlap with diarrhoea prominent Irritable Bowel Syndrome...
New data show positive association between Remsima® SC pre-dose level with efficacy outcomes

New data show positive association between Remsima® SC pre-dose level with efficacy outcomes

Oct 14, 2020

Celltrion Healthcare have announced two new data sets relating to the use of the subcutaneous formulation of infliximab, Remsima® SC (CT-P13 SC), in inflammatory bowel disease (IBD) at a poster presentation at UEG Week Virtual 2020.  The first study investigated the...
Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s Disease

Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s Disease

Oct 14, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson have released Phase 2 interim data from the GALAXI 1 study, which showed TREMFYA® (guselkumab) demonstrated results at week 12 in adult patients with moderately to severely active Crohn’s disease (CD) with...
Roche provide update on phase III studies of etrolizumab in people with ulcerative colitis

Roche provide update on phase III studies of etrolizumab in people with ulcerative colitis

Aug 10, 2020

Topline results have been releases from a phase III study programme evaluating the investigational medicine etrolizumab in people with moderately to severely active ulcerative colitis. Mixed results were seen in studies evaluating etrolizumab as an induction therapy,...
« Older Entries
  • Resource Type

  • Therapy Area

  • Reset

Gold Supporters

Silver Supporters

Supporters fund meetings of the expert group and pay for the services of E4H to provide secretariat support to the group. Supporters have no editorial control over the content of expert group materials except for reviewing the materials to ensure compliance with industry codes of ethical conduct.

Website owned and developed by E4H
Privacy Policy | Terms & Conditions

This site uses cookies: Find out more.